Canine Atopic Dermatitis Market |Size | Share | Trends | Overview | Growth 2022-27

According to IMARC Group’s latest report, titledCanine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027.’ the global canine atopic dermatitis market reached a value of US$ 1.56 Billion in 2021. Canine atopic dermatitis (CAD) is an allergic, inflammatory skin disease in dogs caused by environmental allergens such as grass, mold spores, and house dust mites.  It is highly prevalent in German shepherds, Labradors, golden retrievers and pugs aged six months to three years. It is characterized by symptoms including excessive itching, scratching, skin inflammation, and rubbing and licking, majorly around the face, paws, and underarms. In addition, food ingredients and other insect bites can also trigger the symptoms in dogs.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report

Request for a PDF sample of this report: https://www.imarcgroup.com/canine-atopic-dermatitis-market/requestsample

The market is primarily driven by the rising incidences of atopic dermatitis in dogs triggered due to air pollution and allergens. In addition, the growing awareness among pet owners about early signs and symptoms of allergic reaction and the increasing adoption of pet insurance is positively influencing the market growth. Furthermore, the rapid development of advanced therapeutic methods to control symptoms in animals represents another key factor driving the global market. Moreover, rising environmental factors responsible for allergies and increasing research and development (R&D) investment by the key industry players in the field of veterinary sciences are anticipated to propel the market growth in the upcoming years. Looking forward, IMARC Group expects the market to reach US$ 3.86 Billion by 2027, exhibiting at a CAGR of 16.4% during 2022-2027.

Competitive Landscape:

  • AB Science
  • Bimeda Inc.
  • Bioceltix SA
  • Boehringer Ingelheim International GmbH
  • Ceva Santé Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Phibro Animal Health Corporation
  • Toray Industries Inc.
  • Vetoquinol S.A.
  • Virbac and Zoetis Inc.

Key Market Segmentation:

Breakup by Drug Class Type:

  • Glucocorticoids
  • Immunosuppressants
  • Monoclonal Antibody
  • Others

Breakup by Route of Administration:

  • Topical
  • Oral
  • Injectable

Breakup by Distribution Channel:

  • Veterinary Hospitals
  • Pet Clinics
  • Pharmacies and Drugstores
  • Others

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)

Explore full report with TOC & List of Figureshttps://www.imarcgroup.com/canine-atopic-dermatitis-market

We are updating our reports, If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

Key highlights of the report:                                                           

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • The Impact of COVID-19 on the Global Market
  • Value Chain Analysis
  • Structure of the Global Market
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us                                                                      

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group

30 N Gould St Ste R

Sheridan, WY 82801 USA – Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800